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Abstract 
Background: Current guidelines for the treatment of adult severe traumatic brain injury (sTBI) consist of high-quality 
evidence reports, but they are no longer accompanied by management protocols, as these require expert opinion to 
bridge the gap between published evidence and patient care. We aimed to establish a modern sTBI protocol for adult 
patients with both intracranial pressure (ICP) and brain oxygen monitors in place.
Methods: Our consensus working group consisted of 42 experienced and actively practicing sTBI opinion leaders 
from six continents. Having previously established a protocol for the treatment of patients with ICP monitoring alone, 
we addressed patients who have a brain oxygen monitor in addition to an ICP monitor. The management protocols 
were developed through a Delphi-method-based consensus approach and were finalized at an in-person meeting.
Results: We established three distinct treatment protocols, each with three tiers whereby higher tiers involve thera-
pies with higher risk. One protocol addresses the management of ICP elevation when brain oxygenation is normal. 
A second addresses management of brain hypoxia with normal ICP. The third protocol addresses the situation when 
both intracranial hypertension and brain hypoxia are present. The panel considered issues pertaining to blood trans-
fusion and ventilator management when designing the different algorithms.
*Correspondence:  ghawryluk@hsc.mb.ca 
51 Section of Neurosurgery, University of Manitoba, GB1, 820 Sherbrook 
Street, Winnipeg, MB R3A 1R9, Canada
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Introduction
The Seattle International Brain Injury Consensus Confer-
ence (SIBICC) [1] used a Delphi-method based consen-
sus approach in an attempt to bridge the gap between the 
severe traumatic brain injury (sTBI) guidelines available 
for individual treatments [2] and the lack of evidence on 
how such treatments should be integrated into a practical 
management algorithm. The result, a protocol based on 
the formalized consensus of 42 international, multidisci-
plinary neurotrauma experts, provides class III evidence 
to guide the management of sTBI patients with intracra-
nial pressure (ICP) as their only monitored brain-specific 
parameter [1]. During this process, the group expressed 
a desire to additionally address multi-modality moni-
toring if possible. They strongly supported brain tissue 
oxygen  (PbtO2) monitoring as their first choice for the 
second parameter. Indeed, the evidence suggesting that 
sTBI clinical care informed by  PbtO2 measures may lead 
to improved clinical outcomes is growing [3]. This paper 
thus presents the second product of the SIBICC meeting, 
an algorithm for managing adult sTBI patients based on 
combined monitoring of ICP and  PbtO2.
Methods
The methods were the same as used in the ICP-only 
work (see also supplementary methods) [1]. Forty-
two international intensivists, neurosurgeons, trauma 
surgeons, and emergency medicine physicians from 
six continents comprised the SIBICC consensus 
working group (CWG). We based panel selection on 
(a) > 10  years clinical experience in sTBI; (b) current, 
active involvement in acute care management of sTBI 
patients; (c) representation of involved disciplines; (d) 
geographic diversity; (e) ability to commit time to the 
algorithm development process. We calculated panel 
size based on logistic considerations. Panelists com-
pleted conflict of interest forms relevant to sTBI man-
agement. There were no conflicts mandating recusal of 
any participant.
The expressed focus of the effort was to design a 
management algorithm that would be acceptable to the 
panel and amenable to application in both neurological 
and general ICUs by physicians not specialized in neu-
rointensive care. A priori, we specified that the thresh-
old for consensus would be 80% or greater agreement 
by at least 80% of the voting panelists. Prior to the 
meeting, the CWG completed eight web-based surveys 
(SurveyMonkey Inc., San Mateo, CA, USA, www.surve 
ymonk ey.com) to determine the algorithm design and 
focus, explore definitions and thresholds, operationally 
define treatment modalities, evaluate acceptability and 
tier assignments of treatment modalities, etc. We com-
bined voting results with panelists’ comments to iterate 
these surveys to maximize consensus and define areas 
requiring focus at the in-person meeting. It was during 
this process that the CWG elected to attempt develop-
ment of an algorithm for combined ICP/PbtO2 monitor-
ing if time allowed.
The in-person SIBICC meeting occurred from the 
5th to 7th of April 2019 in Seattle, Washington, USA. 
We used anonymous electronic voting and vote analy-
sis (Electronic Media Services Inc., Gig Harbor Wash-
ington, USA, www.elect ronic meeti ngser vices .com). 
Professional, independent non-physician moderators 
facilitated group discussions. Unless specifically modi-
fied by the CWG, we limited the voting cycle to three 
iterations, interspersed with discussions. An element 
formed part of the final recommendations only if it 
attained 80% approval. Unresolved issues are reported 
as such. We used small group sessions to address com-
plex issues, with the whole CWG modifying and voting 
on small group recommendations. Small group discus-
sions relevant to these ‘combined’ algorithms focused 
particularly on the complexities of ventilator manage-
ment and blood transfusion. All recommendations 
were incorporated verbatim into the final product.
The CWG recognized the notable time and effort 
that the Clinical Standardization Committee involved 
in designing the brain oxygen optimization in severe 
TBI-phase 3 (BOOST-3) trial had devoted to devel-
oping a study protocol to manage combined ICP and 
 PbtO2 abnormalities in the experimental limb of that 
randomized trial. Rather than ignoring the value of 
what they had produced in parallel, relevant aspects 
of the BOOST-3 protocol were reviewed during the 
Conclusions: These protocols are intended to assist clinicians in the management of patients with both ICP and 
brain oxygen monitors but they do not reflect either a standard-of-care or a substitute for thoughtful individualized 
management. These protocols should be used in conjunction with recommendations for basic care, management of 
critical neuroworsening and weaning treatment recently published in conjunction with the Seattle International Brain 
Injury Consensus Conference.
Keywords: Brain injury, Head trauma, Algorithm, Protocol, Consensus, Intracranial pressure, Brain oxygen, Tiers, 
Seattle, SIBICC, PbtO2
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development of the SIBICC algorithm. Discussion was 
facilitated as several CWG members overlapped both 
efforts. Notably, the BOOST-3 protocol was avail-
able for information only, and involved neither effort 
nor implication to adopt or merge any steps. The CWG 
acknowledges the cooperation of the whole BOOST-3 
Clinical Standardization Committee in this process (see 
“Acknowledgements”).
Donations solicited from industry and other interested 
parties funded the in-person meeting. In return, they 
were allowed to silently observe the conference, with-
out any interaction with the panelists or the process. No 
donors or other outside parties influenced any portion of 
these recommendations.
Results
Consensus efforts generated a list of interventions viewed 
as fundamental to the care of sTBI patients and which 
should ideally be in place early in the course of care 
(Fig. 1). These ‘tier zero’ interventions are not dependent 
on the presence of ICP elevation. The CWG also gener-
ated a list of treatments that should not be used in the 
Fig. 1 Consensus-based basic severe traumatic brain injury care for patients with an ICP and brain oxygen monitor in situ. These are basic treat-
ments recommended as fundamental to the care of patients with sTBI, to be initiated (“Expected interventions”) or considered (“Recommended 
interventions”) upon ICU admission of a patient with both an ICP and brain oxygen monitor, regardless of the measured values. CO2 carbon dioxide, 
CPP cerebral perfusion pressure, Hg hemoglobin, HOB head of bed, ICP intracranial pressure, ICU intensive care unit, spO2 arterial oxygen saturation
Table 1 Treatment NOT recommended for use in the man-
agement of  severe traumatic brain injury (when both  ICP 
and  PbtO2 are monitored)
CPP cerebral perfusion pressure, ICP intracranial pressure, kPa kiloPascals, 
PaCO2 arterial partial pressure of carbon dioxide, PbtO2 brain tissue partial 
pressure of oxygen
Mannitol by non-bolus continuous intravenous infusion
Scheduled infusion of hyperosmolar therapy (e.g., every 4–6 h)
Lumbar CSF drainage
Furosemide
Routine use of steroids
Routine use of therapeutic hypothermia to temperatures below 35 °C 
due to systemic complications
High-dose propofol to attempt burst suppression
Decreasing  PaCO2 below 30 mmHg/4.0 kPa
Routinely raising CPP above 90 mmHg
Barbiturates as treatment for low  PbtO2 unless barbiturates are otherwise 
indicated
Hypothermia as treatment for low  PbtO2 unless hypothermia is otherwise 
indicated
Hypercarbia in “type D” patients
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care of patients with sTBI (Table  1), except in special 
circumstances. The additional algorithms provided here 
use the same three-tier algorithm structure as in the ICP-
only algorithm development [1]. To accommodate the 
combination of two monitors, a schema consisting of a 
2 × 2 table combining the permutations of ICP and  PbtO2 
status was used (Fig. 2). The CWG developed individual 
management algorithms for the three types with abnor-
mal monitored values: Fig.  3 presents the algorithm for 
Type B (abnormal ICP and normal  PbtO2), Fig.  4 pre-
sents the algorithm for Type C (normal ICP and abnor-
mal  PbtO2), and Fig. 5 presents the algorithm for Type D 
(both ICP and  PbtO2 abnormal).
The CWG also provides inter-tier recommendations 
(Figs.  3,4,5) and guidance on Critical Neuroworsening 
(Fig.  6) to assist in evaluating and managing patients 
requiring increased therapeutic intensity.
Discussion
As with the first SIBICC effort that produced a manage-
ment algorithm for adult sTBI patients with ICP moni-
toring alone [1], this work uses Delphi process-based 
mechanics to provide basic evidence guiding integration 
of individual treatment modalities into management 
algorithms for patients with combined ICP/PbtO2 moni-
toring. The process amalgamated the practice-based rec-
ommendations of 42 international, experienced, clinically 
active neurotrauma practitioners from those disciplines 
involved in acute post-traumatic (ICU) care by means of 
consensus achieved with blinded voting. Such formalized 
integration of expert opinion provides the most basic 
level of evidence towards organizing and standardizing 
care, relevant to all neurotrauma practitioners but par-
ticularly to centers not specifically expert in the manage-
ment of sTBI or those considering initiating combined 
ICP/PbtO2 monitoring.
Given the class III status of this evidence, these algo-
rithms should be considered as a suggested treatment 
method without proven superiority over other applicable 
methods. They represent a safe and modern approach to 
sTBI care. They are not a standard of care nor are they 
likely to represent the best treatment approach in a given 
instance. They are not legally binding and they are not 
designed as quality assurance monitoring tools. They do 
not represent the approach of any individual CWG mem-
ber and should not be substituted for thoughtful clini-
cal judgment. Variability within individual patients or 
patient cohorts (e.g. center variations) may necessitate 
local adaptation, which is entirely within the nature of 
this offering.
Algorithm structure
The combination of ICP and  PbtO2 monitoring lends 
itself to several possible protocol structures. One 
option is to conceptualize ICP and  PbtO2 management 
separately and to present them as distinct pathways, as 
has been done for the paediatric sTBI guidelines [4, 5]. 
The other is to maintain integration of the two moni-
tors and create separate algorithms for the three patho-
logic combinations of ICP and  PbtO2 status. Our panel 
felt that when high ICP and low  PbtO2 are present con-
currently ideal management would not simply reflect 
a simple combination of care provided when high ICP 
and low  PbtO2 each exist in isolation. In particular, the 
CWG felt that mechanical ventilation requires dis-
tinct management when both high ICP and low  PbtO2 
are present concurrently. In the interest of supporting 
precision medicine and to ease clinical application by 
providing specific, separate protocols for individual 
pathological combinations, we chose to present three 
distinct algorithms (Figs.  2,3,4,5). For a given combi-
nation (type B, C, or D), the relevant protocol should 
be applied. Changes in clinical status should prompt 
adjustment to the newly germane algorithm as well as a 
thoughtful clinical approach.
Conditions of tiered treatment
The use of tiers attempts to balance the benefits and effi-
cacy of an agent against risks inherent to its use. General 
clinical management is considered tier zero. Treatment 
Fig. 2 This matrix provides the schema for the 4 clinical conditions 
encountered in patients with both ICP and brain oxygen monitors 
in situ. Type A reflects normal values for both monitors and does 
not require treatment. Type B involves ICP elevation but normal 
brain oxygen values; we propose a distinct treatment algorithm for 
such patients than in those with ICP elevation and unknown  PbtO2 
values. Type C patients have hypoxic brains but normal ICP and Type 
D patients have both brain hypoxia and ICP elevation.  An ICP of 22 
mmHg discriminates normal (lower) and abnormal (higher) values 
while  PbtO2 values of 20 mmHg discriminates normal (higher) and 
abnormal (lower) values. ICP intracranial pressure,  PbtO2 partial pres-
sure of brain oxygen
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of intracranial hypertension or brain hypoxia will gener-
ally begin at tier one. Movement to higher tiers reflects 
increasingly aggressive interventions. Here, treatments in 
any given tier are considered equivalent, with the selec-
tion of one treatment over another based on individual 
patient characteristics and physician discretion. During 
any given episode being addressed, multiple items from 
a single tier can be trialed individually or in combination 
with the goal of a rapid response. The provider should 
maintain awareness of the duration of any episode and 
consider moving to more aggressive interventions in 
a higher tier quickly if the patient is not responding. In 
Fig. 3 Consensus-based algorithm for the management of severe traumatic brain injury with intracranial hypertension and normal brain oxygena-
tion. Lower tier treatments are viewed as having a more favorable side effect profile than higher tiers and generally should be employed first. Inter-
tier recommendations encourage patient reassessment for remediable causes of treatment resistance. See text for details. CPP cerebral perfusion 
pressure, EEG electroencephalogram, EVD external ventricular drain, ICP intracranial pressure, kPa kiloPascals, MAP mean arterial pressure, PaCO2 
arterial partial pressure of carbon dioxide
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some cases, it might be preferable to skip one or more 
tiers (e.g. choosing to decompress a patient with mid-
line shift due to hemispheric swelling and very high ini-
tial ICP). No individual agent or combination thereof is 
critical to success in managing TBI. Clinical judgment 
must always determine the final management strategy.
Tier‐zero (Fig.  1) recommendations apply to sTBI 
patients who are admitted to an ICU in whom the 
Fig. 4 Consensus-based algorithm for the management of severe traumatic brain injury with brain hypoxia and normal intracranial pressure. Lower 
tier treatments are viewed as having a more favorable side effect profile than higher tiers and generally should be employed first. Inter-tier recom-
mendations encourage patient reassessment for remediable causes of treatment resistance. See text for details. CPP cerebral perfusion pressure, 
EEG electroencephalogram, EVD external ventricular drain, ICP intracranial pressure, kPa kiloPascals, MAP mean arterial pressure, PaCO2 arterial partial 
pressure of carbon dioxide
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decision to concurrently monitor ICP and  PbtO2 has been 
made. Management recommendations for sTBI patients 
without ICP monitoring are published elsewhere [6]. 
The goal of tier‐zero is to establish a stable, neuropro-
tective physiologic baseline regardless of eventual ICP 
or  PbtO2 readings. Tier-zero sedatives and analgesics 
Fig. 5 Consensus-based algorithm for the management of severe traumatic brain injury with intracranial hypertension and  brain hypoxia. Lower 
tier treatments are viewed as having a more favorable side effect profile than higher tiers and generally should be employed first. Inter-tier recom-
mendations encourage patient reassessment for remediable causes of treatment resistance. See text for details. CPP cerebral perfusion pressure, 
EEG electroencephalogram, EVD external ventricular drain, ICP intracranial pressure, kPa kiloPascals, MAP mean arterial pressure,  PaCO2 arterial partial 
pressure of carbon dioxide
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target comfort and ventilator tolerance rather than ICP 
or  PbtO2. Temperature management targets the avoid-
ance of fever (defined by the CWG as core tempera-
ture > 38 °C). Consistent with the BTF Guidelines [2], the 
minimal cerebral perfusion pressure (CPP) threshold is 
60 mm Hg.
The algorithm for type B patients differs from that rec-
ommended for the management of intracranial hyper-
tension in patients with ICP-monitoring alone [1] due 
to available  PbtO2 evidence that cerebral hypoxia is not 
present. Although tiers one and two are the same as for 
the ICP-only algorithm, this difference is reflected in 
the recommendation that hyperventilation to a  PaCO2 
of 30–32  mmHg/4.0–4.3  kPa can be considered in tier 
three. The CWG does not recommend either hypertonic 
saline or mannitol as preferable and uses the same limits 
for serum sodium and osmolality for both agents. They 
recommend CSF drainage if an external ventricular drain 
is available and consideration of placing one if other 
means are used to monitor ICP. They also recommend 
considering the possibility of seizures as the etiology of 
intracranial hypertension in tier one.
The CWG recommends consideration of a trial of 
neuromuscular blockade (with continuation if it is effec-
tive) as a tier two intervention. They also support mild 
hyperventilation  (PaCO2 32–35  mm Hg/4.7  kPa) at 
this level. The CWG also recommends the considera-
tion of autoregulation testing via CPP manipulation to 
Fig. 6 Critical neuroworsening and its management. SIBICC definition (upper box), response (middle box) and a list of suggested differential diag-
noses (bottom) surrounding critical neurological deterioration (critical neuroworsening). CNS central nervous system, GCS Glasgow Coma Scale, ICP 
intracranial pressure
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determine whether CPP augmentation might be appli-
cable. The MAP challenge is performed under stable 
conditions to prevent confounding (e.g., no other active 
changes in care should be made during the challenge, 
including adjustments in sedation, analgesia, EVD drain-
age or other physiological parameters). To perform the 
challenge [7]:
  • Record baseline monitor parameters at the beginning 
of the challenge (e.g., ICP, MAP and CPP).
  • Initiate or titrate a vasopressor to increase the MAP 
by 10 mm Hg for up to 20 min.
  • Observe the interaction between the MAP, ICP, CPP 
and  PbtO2 during the challenge.
  • Record monitor parameters at the end of the chal-
lenge.
  • Evaluate the observed responses and recorded values 
for evidence of sPAR status. Disrupted sPAR will pre-
sent as a sustained increase in ICP with MAP eleva-
tion.
  • Adjust the target MAP back to baseline (disrupted 
sPAR) or to the chosen new, elevated target (intact 
sPAR).
As noted above, tier three treatment in type B par-
allels that for ICP-monitor-only sTBI patients, with 
the exception that moderate hyperventilation  (PaCO2 
30–32 mmHg/4.0–4.3 kPa) is also included.
Type C treatments include interventions known to 
directly or indirectly improve  PbtO2 values, largely based 
upon the collective experience of the expert CWG. A 
great deal of discussion surrounded augmentation of 
oxygenation in terms of benefit versus toxicity and the 
possibility that higher monitor readings may not par-
allel improved oxygen availability when  FiO2 or  PaO2 
are pushed very high.  FiO2 can effectively increase 
 PbtO2 values. Although the CWG approved upward 
 FiO2 adjustment to 60% at tier one, further oxygenation 
manipulation was left to the discretion of the physician 
in terms of manipulation of ventilator dynamics, PEEP, 
 FiO2, etc. Therefore, at tier two, elevating the  PaO2 up 
to 150 mm Hg is recommended but the means is meant 
to be fine-tuned to the patient. Further elevation of the 
 PaO2 was controversial but the final decision was to rec-
ommend normobaric hyperoxia above 150 mm Hg at tier 
three.
The notion of blood transfusion to ameliorate low  PbtO2 
values also generated significant discussion. Harm from 
the transfusion of blood products is increasingly recog-
nized [8, 9] and many on the panel felt that transfusion 
had little impact on  PbtO2 values in their experience. The 
CWG finally settled on limiting blood transfusion to tier 
three, recommending consideration of transfusing one 
unit of PRBCs in the setting of a  PbtO2 < 20 mm Hg and 
an Hgb < 9 g/L. It was acknowledged that blood transfu-
sion would be a stronger consideration in patients with 
active organ ischemia (eg. cardiac ischemia).
Other recommendations in type C differ from those 
in type B patients. First-tier recommendations include 
setting the target CPP at the upper limit of the gener-
ally accepted range of 60–70  mm Hg as blood pressure 
augmentation can be an effective strategy for increasing 
 PbtO2. The avoidance of hypocarbia is also stressed in tier 
one; hypercarbia induces vasodilation which can improve 
 PbtO2 though this strategy increases intracranial blood 
volume and risks ICP elevation. At tier two, the CWG 
supported consideration of setting an ICP threshold 
below the general target of 22  mm Hg (acknowledging 
that this group does not have intracranial hypertension 
by definition). They also allowed compliance manipula-
tion via CSF drainage.
Type D recommendations combine ICP and  PbtO2 
treatments, but aim to limit those treatments that 
would exacerbate either pathology. At tier one, there-
fore, although the CWG supported elevation of the 
 FiO2 to 60% and setting the CPP threshold to the upper 
limit of the normal range (i.e., 70 mm Hg), they recom-
mended against hyperventilation to any degree which 
could worsen  PbtO2. In tier two, the CWG recommended 
raising the  PaO2 to as high as 150 mm Hg in addition to 
considering neuromuscular blockade and CPP manipula-
tion based on autoregulation testing but did not support 
lowering the ICP threshold. At tier three, they com-
bined ICP-based recommendations for pentobarbital/
thiopentone coma or decompressive craniectomy with 
 PbtO2-based treatments including normobaric hyperoxia 
to above 150  mm Hg and limited transfusion. Notably, 
decompressive craniectomy can enable more aggressive 
 PbtO2 augmentation strategies such as hypercarbia which 
can exacerbate ICP; it can also mitigate the intracranial 
hypertension associated with MAP augmentation in 
patients who are not autoregulating.
The CWG carried forward those items that they did 
not recommend for treating intracranial hyperten-
sion in ICP-Only patients (Table  1). They added three 
 PbtO2-specific items to this list. They recommended 
against using high-dose barbiturates or cooling specifi-
cally for the management of  PbtO2 though these therapies 
can be thoughtfully administered for other indications. 
They also recommended against routinely using hyper-
carbia  (PaCO2 > 45  mm Hg/6.0  kPa in type D patients 
given the risk of elevating ICP.
Inter‐tier recommendations
Stepping to a higher tier is a potential indicator of 
increased disease severity. As higher tiers represent 
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interventions with increased associated risks, the CWG 
recommends reassessing the patient’s basic intra-and 
extra-cranial physiologic status and reconsidering the 
surgical status of intracranial mass lesions (e.g. contu-
sions) not previously considered operative. If the patient 
is at a non‐specialist center at the point of upward tier 
advancement, the CWG recommended considering con-
sultation with and potential transfer to a TBI center with 
increased resources if possible within the regional health-
care environment. When desired, transfer is best com-
pleted before clinical decline precludes it.
Critical Neuroworsening represents a specific situation 
of critical deterioration requiring emergent evaluation 
and management. ‘Neuroworsening’ was first defined as 
a potential intermediate-outcome variable for TBI trials 
[10], it was adapted for the BEST:TRIP trial [11] and sub-
sequent management studies for limited resource envi-
ronments [6]. The CWG modified the criteria, terming 
the new criteria ‘Critical Neuroworsening’ and added it 
to promote its recognition as a critical event and guide 
expeditious evaluation and consideration of empiric 
therapy.
Summary
As with the recently published SIBICC ICP-Only algo-
rithm [1], this effort provides a bridge between the aca-
demic value of formal evidence reports [2] and practical, 
bedside management. It relies on “medicine-based-evi-
dence” gleaned from 42 experienced, currently practicing 
experts, rigorously synthesized using a Delphi-method-
based consensus process. The CWG agreed that  PbtO2 
should be the second monitored variable after ICP, rep-
resenting a step toward multi-modality monitoring. 
These recommendations represent the lowest level of evi-
dence—a form of multi-physician curbside consult—and 
are presented as a framework for adoption or adaption 
by trauma systems or medical centers toward developing 
organized, protocol-based approaches to adult sTBI man-
agement. They are not binding and should not be viewed 
as the only or necessarily the best method of manage-
ment of sTBI. They are offered as guidance only, as a first 
attempt at filling a gap in the current clinical literature.
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